Jones Trading Maintains Buy on Enliven Therapeutics, Raises Price Target to $70

Benzinga Newsdesk www.benzinga.com Positive 84.1%

Neg 0% Neu 0% Pos 84.1%

Jones Trading analyst Boris Peaker maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $45 to $70.